COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

Perspective on the clinical potential of mass spectrometry-based proteogenomics

Is DNA sequencing enough to recommend personalized treatments for cancer patients? In a article published in Nature Reviews Clinical Oncology, CPTAC investigators and colleagues from the Fred Hutch, Baylor College of Medicine, and University of Washington Medicine make the case for proteogenomics - analysis of the genomic and proteomic changes in cancer tumors.

A key aspect of the perspective article, is that the authors show how both types of data can be used to better understand individual cancers and treatments. The authros discuss the added value of proteogenomics over the purely genome-driven approach to the clinical characterization of cancers and summarize ongoing efforts to incorporate targeted proteomic measurements based on selected/multiple reaction monitoring (SRM/MRM) mass spectrometry (MS) into the clinical laboratory to facilitate clinical proteogenomics.

This perspective article was published in Nature Reviews Clinical Oncology.